BENLYSTA patient story

Dr. Elaine Lambert, Rheumatologist.

Paid consultant to GSK at the time of filming.

video transcript

DR. LAMBERT: I’m Elaine Lambert. I’m a private practice Rheumatologist in San Mateo, California.

ON-SCREEN TEXT: Dr. Elaine Lambert, Rheumatologist
Paid consultant to GSK at the time of filming.

ON-SCREEN TEXT: Meet a patient on BENLYSTA
BENLYSTA
(belimumab)
Intravenous Use 120 mg/vial
Subcutaneous Use 200 mg/mL
Stay tuned for Important Product Information.

ON-SCREEN TEXT: Dr. Elaine Lambert, Rheumatologist
Paid consultant to GSK at the time of filming.

DR. LAMBERT: A patient of mine that I started on BENLYSTA very early when it was first released is a African-American woman who I met because we were both working at the same hospital. So I had met her actually when she was engaged, before she had lupus, and then after her marriage, she developed lupus and had very severe tendonitis such that I sometimes would have to put her in a cast because of the severity of the pain. A lot of arthritis, a lot of very severe skin manifestations, One of the difficult things to control in her disease flares were her high fevers, and they would really only respond to high dose glucocorticoids. We really tried all the immunosuppressive drugs that are steroid sparing, and she didn’t tolerate them, or they didn’t work.

ON-SCREEN TEXT: Significant disease activity

DR. LAMBERT: And so, when BENLYSTA came out, I thought this was a really good option of a medication that might give her the kind of control we needed, so that she didn’t need to be on such high doses of glucocorticoids. She had developed diabetes and gained a lot of weight, had a lot of side effects from the glucocorticoids. So, she was anxious to try the BENLYSTA, she went on it, it was clear that we were able to really taper the glucocorticoids, and she’s been able to remain on a very low dose now with occasional flares, but she doesn’t need to go up on the glucocorticoids as much as she needed in the past.

ON-SCREEN TEXT: In its pivotal trials, BENLYSTA reduced disease activity and the risk of severe flares

ON-SCREEN TEXT: In the BENLYSTA pivotal trials, steroid reduction was not statistically significant between treatment groups. Treatment results may vary.

DR. LAMBERT: Click on the link for more information.

ON-SCREEN TEXT: BENLYSTAHCP.com

VOICEOVER:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5 years with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active central nervous system lupus. Reported: serious & sometimes fatal infections; progressive multifocal leukoencephalopathy; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

ON-SCREEN TEXT:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5+ with active SLE or active lupus nephritis. Not for use in severe active CNS lupus. Reported: serious & sometimes fatal infections; PML; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

ON-SCREEN TEXT:
BENLYSTA
(belimumab)
Intravenous Use 120 mg/vial
Subcutaneous Use 200 mg/mL

GSK Logo

Trademarks are owned by or licensed to the GSK group of companies.
©2023 GSK or licensor. BELVID230009 August 2023 Produced in USA.

You may also like

BENLYSTA patient story

Dr. Don Thomas, Rheumatologist

BENLYSTA in my practice

Dr. Grace Wright, Rheumatologist

Icon: Computer

Join us for a live webinar

Learn more